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Abstract
Background: Demand for primary care (PC) services in Spain exceeds available resources. Part of this strong demand is due
to the high prevalence of emotional disorders (EDs)—anxiety, depression, and somatic symptom disorders—and related
comorbidities such as pain or chronic illnesses. EDs are often under- or misdiagnosed by general practitioners (GPs) and,
consequently, treatment is frequently inadequate.
Objective: We aim to compare the short- and long-term effectiveness of group-delivered transdiagnostic cognitive behavioral
therapy (TD-CBT) versus treatment as usual (TAU) in the treatment of EDs in the PC setting in Spain. We also aim to compare
the effect of these treatments on disability, quality of life, cognitive-emotional factors, and treatment satisfaction.
Methods: Here we present the study design of a two-arm, single-blind, randomized controlled trial (N=1126) to compare TAU
to TD-CBT for EDs. TAU will consist primarily of pharmacological treatment and practical advice from the GP while TD-CBT
will be administered in seven 90-minute group sessions held over a period ranging from 12 to 14 weeks. Psychological assessments
are carried out at baseline (ie, pretreatment); posttreatment; and at 3-, 6-, and 12-month follow-up. The study is conducted in
approximately 26 PC centers from the National Health System in Spain.
Results: This study was initiated in December 2013 and will remain open to new participants until recruitment and follow-up
has been completed. We expect all posttreatment evaluations to be completed by December 2017, and follow-up will end in
December 2018.
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Conclusions: We expect the TD-CBT group to have better results compared to TAU on all posttreatment measures and that
this improvement will be maintained during follow-up. This project could serve as a model for use in other areas or services of
the National Health System in Spain and even in other countries.
ClinicalTrial: International Standard Randomized Controlled Trial Number (ISRCTN): 58437086;
http://www.isrctn.com/ISRCTN58437086 (Archived by WebCite at http://www.webcitation.org/6mbYjQSn3)
(JMIR Res Protoc 2016;5(4):e246)   doi:10.2196/resprot.6351
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Introduction
Background and Rationale
Emotional disorders (EDs), including mood, anxiety, and
somatization disorders, are a leading cause of disability and
demand for primary care (PC) services [1,2]. According to Haro
et al [1], 1-year prevalence rates in Spain for anxiety, depression,
and somatization disorders are 6.2%, 4.4%, and 14.7%,
respectively. In Spanish PC centers, the 1-year prevalence rates
for depression, mood disorders, and mental disorders are 9.6%,
13.4%, and 31.2%, respectively [3]. These data indicate that
approximately 1 out of 3 patients in the PC setting suffers from
some type of mental disorder. In addition, comorbidity in these
patients is high [4-6] and closely associated with poor quality
of life [7], substance misuse, disability, and high health and
social costs that rise in parallel with the increase in the number
of comorbid disorders [8].
In 2001, the World Health Organization (WHO) estimated that
the prevalence of mental disorders would continue to increase
through the year 2020, thus imposing a significant social and
economic burden on many countries around the world, especially
in developed countries. For this reason, the WHO stressed the
need to increase the number of specialized human resources to
treat patients with EDs [9]. The most recent guidelines for
depression and anxiety disorders published by the National
Institute for Health and Clinical Excellence (United Kingdom)
[10] recommend an evidence-based approach to identify the
least intrusive but most effective interventions for the
management of these disorders.
Cognitive behavioral therapy (CBT) is a highly efficacious and
cost-effective approach to managing EDs; for this reason, it is
currently considered the optimal therapy to treat these disorders.
Although CBT is less expensive than most medical treatments,
the costs can be further reduced by using a transdiagnostic group
approach in which patients with different but related EDs (ie,
they share certain commonalities, particularly high levels of
anxiety and maladjusted thoughts) are grouped together [11].
This approach, known as transdiagnostic cognitive behavioral
therapy (TD-CBT), addresses dysfunctional behaviors and
thoughts with the aim of changing behavioral and thinking
patterns. TD-CBT has been shown to be more effective than
treatment as usual (TAU) in PC settings for the treatment of
depression [12] and anxiety [13]; it has also been shown to be
comparable or superior to many evidence-based psychological
interventions for pain [14], especially when patients are referred
by their general practitioners (GPs) [15].
Many patients with EDs are users of both PC and specialized
care services. However, in many cases patients are
misdiagnosed, with misdiagnosis rates of up to 78% for
depression [16], 86% for panic disorder, 71% for generalized
anxiety disorder (GAD), and 98% for social anxiety disorder
[16,17]. Consequently, many patients may not receive
appropriate treatment. Moreover, in the case of incorrect
diagnoses, patients may also be subjected to costly, unnecessary,
and potentially addictive and/or harmful (due to side effects)
psychopharmacological treatments [16].
In Spain, the diagnosis of an ED is usually first made by the GP
who must decide, in a very brief consultation (ie, less than 7
minutes), which psychoactive drugs to prescribe (if any) and
whether or not the patient needs specialized care [18]. As a
result of these time constraints, the most common treatments
are pharmacological interventions. According to Codony et al
[19], 39% of patients with anxiety disorders do not receive any
treatment, one-third of patients receive medication alone, only
1% receive psychological therapy, and 27% receive combined
psychological-medical therapy. These findings indicate that
psychological treatment is underprescribed—often only as a
last resort—in patients with an ED who seek help from their
GP.
Despite the generalized underutilization of psychological
treatments in the PC setting, in recent years, several
countries—notably, the United Kingdom—have incorporated
psychological services (including CBT) into the PC setting. In
the last decade, the UK government developed and implemented
a large-scale program entitled Improving Access to
Psychological Therapies (IAPT) [20], designed to improve
treatment of EDs among the general population. The results of
that program have shown that CBT is as effective in routine PC
as it is shown to be in research trials; importantly, these excellent
results were achieved without any side effects, fewer relapses,
and lower long-term economic and social costs than TAU [21].
The benefits of these psychological interventions include their
effectiveness in reducing symptoms associated with depression
and anxiety—effect size in pre-post treatment of 1.39 for anxiety
problems and 1.41 for depression—and high recovery rates for
those who completed treatment—74% for anxiety and 76% for
depression. These benefits have helped to decrease the risk of
relapse while maintaining long-term positive outcomes [22].
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This efficient and novel way of providing patients with access
to psychological therapies in the United Kingdom, where the
most cost-effective treatment has improved the detection,
diagnosis, and referral rates for these common mental health
disorders, has generated intense interest in many countries as a
treatment model, including in Spain. However, efforts are
needed to implement this model in Spain.
Objectives
Primary Objectives
Given the strong evidence base in favor of CBT versus TAU,
together with the need to improve ED treatment in the PC setting
in Spain, the major aim of the Psicología en Atención Primaria
(PsicAP) study is to verify if a group-delivered TD-CBT for
EDs is more effective and efficient than TAU in Spanish PC
centers. If it is so, we want to compare the short- and long-term
efficacy of TD-CBT versus TAU in the treatment of these
disorders.  
Secondary Objectives
We also aim to compare the effect of these treatments on
disability, quality of life, cognitive-emotional factors, and
treatment satisfaction.
Hypothesis
Regarding the primary objectives of this study, the experimental
group as compared to the control group is expected to report a
greater decrease (including pre-post treatment differences and
decrease at 3-, 6-, and 12-month follow-up) in dysfunctional
emotional symptoms and percentage of cases with probable
EDs. The total scores of anxiety, panic, depressive, and somatic
symptoms will be measured by the Patient Health Questionnaire
(PHQ) [23,24]. In addition, regarding the secondary objectives
of this study, we hypothesize that the results will prove that
TD-CBT reduces disability and that it, consequently, improves
quality of life. We expect that participants allocated to the
experimental group will report decreased impairment on work,
family, and social domains and an increase in physical,
psychological, social, and environmental quality of life at
posttreatment and at 3-, 6-, and 12-month follow-up. We also
expect that, relative to the control group, participants in the
experimental group will have higher levels of emotional
regulation and lower scores on cognitive-emotional factors such
as ruminative thinking, worries, metacognitions, and cognitive
biases associated with EDs. Moreover, we expect the
experimental group to report higher treatment satisfaction (see
detailed explanation in the Outcomes sections below).
Study Design
This is a two-arm—TAU control group and TD-CBT
experimental group—single-blind randomized controlled trial
(RCT); the psychologists responsible for assessing patients at
the pre- and posttreatment evaluations are blinded to the
treatment group. The experimental group will also include
patients currently receiving TAU, which will be withdrawn if
they are randomized to the TD-CBT group (see detailed
explanation in the Interventions section below).
Treatment will be assessed at five time points: pretreatment
(before randomization), posttreatment (at the end of the TD-CBT
group session, 3-4 months after treatment initiation), and at
three follow-up evaluations—3, 6, and 12 months after treatment
finalization.
Methods
Study Setting
In Spain, as in many countries, PC is the first level of access to
the public national health system. Following a communitarian
vision of health care, PC is a level of care at which each patient's
condition (and the course of disease) is monitored within the
social environment. All PC centers are organized into basic
structures of health—a health service concept established with
the delimitation of territorial areas of health—in coordinated
multidisciplinary teams (ie, GPs, nurses, pediatricians, social
workers, and physiotherapists), with healing activities integrated
with health promotion, disease prevention, etc. Every patient is
assigned to a PC center of his or her basic structure of health
and, therefore, to a team of carers at each PC center, a
specialized center, and a hospital, covering all levels of possible
need for health assistance. Nevertheless, clinical psychologists
are not part of the PC team, but rather are located in specialized
care units and hospitals.
The clinical trial is being conducted at the following 26 PC
centers in Spain: Madrid (11 centers), Valencia (five centers),
Biscay (one center), Albacete (one center), Mallorca (one
center), Andalusia (two centers), Cantabria (one center), Navarra
(two centers), and Galicia (two centers). These centers share
many common characteristics, but several differences may exist
between them, such as language (eg, Spanish [Castilian],
Basque, Galician or Catalan) and other sociodemographic
differences. As a result, this wide variety of locations makes
these PC centers truly representative of Spanish society as a
whole. The study may be extended to other centers in other
cities around Spain given the interest in offering an alternative
to TAU by PC health professionals.
Target Population
The total sample is expected to consist of 1126 adults, all of
whom will have a diagnosis of anxiety, depression, and/or
somatic symptom disorders. Any anxiety disorder (eg, panic
with or without agoraphobia, GAD, obsessive compulsive
disorder, posttraumatic stress disorder, specific phobias, and
social phobia) and other conditions included under somatization
(eg, medically unexplained symptoms, chronic fatigue, or pain)
may be included in the trial if they are not severe. We will test
severity according to specific measures of disability and severity
of the emotional distress group (see detailed explanation in the
Outcomes section below).
Patients with a confirmed or suspected diagnosis of any of these
disorders are invited by their GP to participate in the study. In
addition, all patients who visit one of the participating PC
centers will have the opportunity to be screened to see if they
qualify for participation. If they meet the inclusion criteria, they
are asked to participate and are included in the trial if they agree.
Before inclusion, patients are informed that they will be
randomly assigned to either the control (TAU) or the
experimental group (TD-CBT). Written informed consent is
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obtained from all patients. Participation is voluntary and
confidentiality is guaranteed. The study protocol
(ISRCTN58437086) has already been approved by the ethics
and clinical research committee of the participating PC centers
and by the Corporate Clinical Research Ethics Committee of
Primary Care of Valencia (CEIC-APCV), the national research
ethics committee coordinator. Participation in this trial does not
involve any added risks to patients apart from the inherent risks
associated with pharmacological treatment (TAU group only).
The aim of this study is to maximize benefits and reduce
potential harms (principle of proportionality) through TD-CBT.
Inclusion and Exclusion Criteria
Inclusion Criteria
Any adult patient between 18 and 65 years of age seeking
treatment for anxiety, depression, and/or somatic symptom
disorder at any of the participating Spanish PC centers may be
included in the study. Participation in the study is completely
voluntary. For diagnosis, patients must meet predetermined
cutoff points on the relevant subscale(s) of the PHQ [23,24].
The 15-item Patient Health Questionnaire (PHQ-15) (<10
points), the 9-item Patient Health Questionnaire (PHQ-9) (<12
points or original algorithm), the 7-item Generalized Anxiety
Disorder (GAD-7) scale (<10 points), and the Patient Health
Questionnaire-Panic Disorder (PHQ-PD) (modified algorithm)
[25] are used to detect somatization disorders, major depressive
disorder (MDD), GAD, and panic disorder, respectively (see
Outcome sections below for details).
Exclusion Criteria
Patients over 65 years of age are excluded from the trial to avoid
distorting the outcomes due to age-related difficulties; however,
once the treatment has been validated, this important part of the
population will be eligible for participation in these treatment
program. Other exclusion criteria include the following: severe
mood disorders (eg, bipolar disorder [GP diagnosis] or severe
MDD: PHQ-9<23); substance abuse or dependence; any other
severe mental disorder (eg, personality disorder); a history of
frequent or recent suicide attempt(s); a high level of disability
(Sheehan Disability Scale [SDS]<25) [26]; difficulty
understanding the Spanish language; intellectual disability;
difficulties in undertaking the group therapeutic process; or
participation in another clinical trial.
Interventions
Treatment-as-Usual Condition
The control group will receive TAU as provided by the GP at
the Spanish PC center. This treatment has been described in
previous research as nontreatment, standard treatment,
pharmacological treatment, and/or practical advice by the GP
delivered in routine care [27], focused on reducing negative
emotional symptomatology.
The TAU is provided by the GP in their regular consultation,
generally consisting of a face-to-face session (5-7 minutes) to
assess the physical and/or psychological complaints of the
patient. Also in this time, the GP will provide advice,
medication—antidepressant, anxiolytics, or hypnotics—and/or
onward referral to specialized care services. Importantly, since
this is TAU, conditions are the same as in routine daily practice
at the treatment center, without any modifications. If the GP
recommends psychological treatment as part of the routine TAU,
such patients are excluded from the final trial recruitment to
avoid bias.
Experimental Condition
Rationale and Goals
The experimental group will receive TD-CBT group therapy.
A well-documented and evidence-based therapeutic approach
[11,22] that has been specially designed by Cano-Vindel [28]
for the treatment of EDs in PC is used. This TD-CBT is focused
on reducing negative emotional symptomatology in the short
term using cognitive restructuring and behavioral management,
which allows patients to continue without the use of medications
in the long term. Any patient receiving TAU prior to study
enrollment and then allocated to the TD-CBT group will be
withdrawn from TAU. This means that patients in both groups
may receive TAU before enrollment in the trial. Once patients
are assigned randomly to the TD-CBT group, the GP is not
permitted to provide or increase the TAU (ie, increasing
pharmacotherapy), but may reduce or eliminate the medication
if improvement is noted. It is expected that the pharmacological
treatment in patients who are allocated to the TD-CBT group
will be withdrawn by the GP as a result of improvement (ie,
reduction) of the negative emotional symptoms due to TD-CBT.
Procedure and Schedule
Each participant will receive seven 90-minute sessions of
TD-CBT group therapy—8-10 patients in each group, during
approximately 12 weeks (3 months). This 12-week treatment
period may be increased if necessary for scheduling purposes
(ie, due to holiday periods) up to a maximum of 16 weeks (4
months). Sessions are facilitated by one clinical psychologist
in a spacious and comfortable room at the PC center. The
therapy is delivered with patients and therapist sitting in a circle.
Space will also be needed for a relaxation session, and will
include a CD player and mats. Paper material is provided for
each session and patients may be required to bring a personal
notebook. Table 1 shows the intervention schedule and the
material provided in each treatment session.
The components of TD-CBT include the following: (1)
Psychoeducation and information, designed to counteract
misconceptions about emotions or EDs by providing correct
information about EDs and treatment aims; (2) Relaxation,
consisting of a series of techniques including training
participants in progressive muscle relaxation, abdominal
breathing, and visualization to reduce EDs and physical arousal;
(3) Cognitive restructuring techniques to modify misconceptions
about EDs; (4) Behavioral therapy to help participants learn to
identify unadjusted emotions and behaviors in order to replace
these with healthier ones; and (5) Relapse prevention to
overcome difficulties and consolidate learning. All the
components are shown in Table 2 with scheduling shown in
Table 3.
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Table 1. Schedule for the 7 treatment sessions.
Material providedScheduleSession
Presentation and group therapy rules
Breathing and relaxation information sheet
Breathing and relaxation self-register
First weekSession 1
CD relaxation
Cognitive restructure information sheet
Activities self-register
Second weekSession 2
Down arrow exercise
Cognitive biases information sheet
Third weekSession 3
Thought purification exerciseFifth weekSession 4
Interpersonal solution problems sheetSeventh weekSession 5
Reinforcement of previous activitiesNinth weekSession 6
Relapse prevention exerciseTwelfth weekSession 7
Table 2. Components of the group TD-CBTa protocol.
SessionComponents of each modulePsychological techniques
1 and 2Information about the following:
• anxiety and mood state
• emotional disorders
• the group therapy
• treatment components and the treatment aims
• cognitive biases
• the relationship between thoughts and emotions
• Counteraction of the following:
• misconceptions of emotions
• misconceptions of emotional disorders
Psychoeducation
1 and 2Abdominal breathing
Training progressive muscle relaxation
Visualization
Relaxation
3, 4, 5, 6, and 7ABC Ellis Model
Information about irrational and rational thoughts
Exercises for the following:
• detection and refutation of irrational thoughts with rational thoughts
• detection of cognitive biases
• to restructure cognitive biases
• to provide positive self-instructions
Cognitive restructuring techniques
5, 6, and 7Behavioral activation
Exposure therapy
Social skills and assertiveness
Solutions problems
Behavior therapy
7Acceptance of relapse
Restructure of relapse
Relapse prevention
aTD-CBT: transdiagnostic cognitive behavioral therapy.
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Table 3. Schedule of the sessions.
SessionPsychological techniques
7654321
XXPsychoeducation
XXRelaxation
XXXXXCognitive restructuring
XXXXBehavior therapy
XRelapse prevention
Therapist Training
All therapists are experienced clinical psychologists. To work
as a clinical psychologist in the National Health System in Spain,
it is necessary to be certified as a Psychologist Specialist in
Clinical Psychology. To obtain this certification, the therapist
must have a university degree in psychology (4-5 years) and
then must undergo a residency program—Internal Resident
Program (IRP)—which is a postgraduate paid training system.
The IRP consists of 4 years of work and training under the
supervision of a specialist in the Spanish National Health
System. In addition to this training, the clinical psychologists
in this trial will also undergo a standardized training course
conducted by a supervisor and trainer, who would have a PhD
in clinical psychology. This training consists of studying the
Therapist Manual, four Internet-based lessons on the content
of each session, and one face-to-face session with the trainer.
This must be completed before the clinical psychologist can
provide any group therapy as part of the trial. All groups are
supervised by one coordinator in each province. Follow-up
sessions are conducted as necessary (ie, by request) to resolve
any doubts after finalization of the training course.
To reduce attrition rates after the final posttreatment assessment,
a clinical psychologist will telephone patients every 6 weeks
posttreatment. During the 10-15-minute telephone consultation
with patients in the TD-CBT group, the clinical psychologist
will reinforce the psychological techniques taught during the
group sessions and will follow up on the participants' emotional
state. In the control group (TAU), the clinical psychologist will
assess patients' emotional state and, if appropriate, recommend
that they visit their GP.
Primary Outcomes
The Patient Health Questionnaire
The PHQ [23] is a screening test derived from the Primary Care
Evaluation of Mental Disorders (PRIME-MD) test, a
self-reported measure of mental disorders designed for use in
PC centers. We will use the Spanish version validated by
Diez-Quevedo et al [24] to screen for EDs, using the sum scores
of all the subscales independently, with some exceptions as
explained below.
Somatization Disorder
The PHQ-15 was derived from the original PHQ studies and is
commonly used to assess somatic symptom severity and the
potential presence of somatization and somatoform disorders
[29]. In the Spanish version, patients are asked to respond to 13
somatic symptoms, scored from 0 to 2 as follows: 0 (not
bothered), 1 (bothered a little), or 2 (bothered a lot). Two items
from the depression module (sleep and tiredness) will be added
and scored as follows: 0 (not at all), 1 (several days), or 2 (more
than half the days or nearly every day). The maximum score
for the PHQ-15 will be 30. A probable somatization disorder is
diagnosed when respondents score 2 points on at least five of
the first 13 symptoms and the two items from the depression
module, with a cutoff point of 10. Using this criterion, the
PHQ-15 has a sensitivity of 78% and specificity of 71% for
somatization disorder [30,31]. One study has shown that patients
with somatization disorder (PHQ-15 diagnosis) utilize twice
the amount of PC services as nonsomatizing patients, at twice
the expense [30]. We used the Spanish language version of the
original PHQ-15 included in the original PHQ [23].
Depression
The PHQ-9 [32] is a specific screening tool for depression in
which participants use a 4-point Likert scale to respond to nine
items (Fourth Edition of the Diagnostic and Statistical Manual
of Mental Disorders [DSM-IV] criteria) about difficulties
experienced during the prior 2 weeks. Using a cutoff of 10
points, the PHQ-9 has a sensitivity of 88% and specificity of
88% for depression. A score between 10 and 14 indicates minor
depression, dysthymia, or moderate MDD; scores between 15
and 19 indicate moderately severe MDD; and scores between
20 and 27 indicate severe MDD. Participants who score between
20 and 23 will undergo a second-order assessment conducted
by a clinical psychologist; in these cases, the Structured Clinical
Interview for DSM Axis-I Disorders (SCID-I) scale for MDD
(Spanish version) [33] is used to confirm the existence of severe
MDD. Participants who score between 24 and 27 on the PHQ-9
and are confirmed by the SCID-I as having severe MDD are
excluded from participation in the trial and referred again to
their GP for referral to specialized care.
In a separate study [34], we studied the psychometric properties
in a subsample of the larger PsicAP sample (n=178) and we
found an optimal cutoff score of 12 on the PHQ-9, with a
sensitivity and specificity of 84% and 78%, respectively.
Nevertheless, using the original algorithm, the sensitivity and
specificity values were 88% and 80%, respectively, thus
recommending the use of the original algorithm due to its
superior psychometric properties [34].
Panic Disorder
The PHQ-PD includes the DSM-IV-based panic disorder
symptoms [23,24,35]. A diagnosis of probable panic disorder
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is made when the participant responds affirmatively to the first
four items on the scale and to four or more of the symptoms.
Nevertheless, when we studied the psychometric properties of
this module in a subsample of the large PsicAP sample [25],
we obtained better sensitivity (77%) and specificity (72%) using
a modified algorithm as follows: when participants respond
affirmatively to the first screening item, to one of the three items
on the next scale, and to four or more items of the somatic
symptoms [25].
Anxiety
The GAD-7 scale is used to measure GAD and other anxiety
disorders [36]. In this scale, patients rate the frequency of
anxiety symptoms during the past 2 weeks. Total scores of 5,
10, and 15 indicate mild, moderate, and severe anxiety,
respectively. The maximum score is 21 and the cutoff score is
8—a score of at least 2 on the first question, plus three more
items. Using a cutoff of 10, the GAD-7 scale has a sensitivity
of 89% and a specificity of 82% for GAD [36].
In our study, we used the validated Spanish version of the
GAD-7 scale [37] instead of the PHQ items related to anxiety
disorders. Factor analysis of the Spanish version of the GAD-7
scale has shown that all items in the GAD-7 scale load onto one
factor and the scale uses a cutoff score of 10 to detect GAD
[37]. In addition, when we evaluated the psychometric properties
of this GAD-7 version in our PC subsample, an optimal cutoff
score of 10 was obtained, showing a sensitivity of 87% and a
specificity of 78% [34].
Eating Disorders and Alcohol Abuse
The PHQ also contains screening items to detect eating disorders
such as bulimia nervosa or binge eating disorder and to check
for the presence of alcohol abuse. If items 6(a)-(c) and 8 are
scored as a “yes,” the score is considered positive for bulimia
nervosa; for binge eating disorder, the criteria is the same except
for item 8 (either “no” or left blank). The Spanish version of
the PHQ was used, which has a sensitivity of 92% and a
specificity of 98% for any eating disorder [24]. Alcohol abuse
is detected if the patient answers “yes” to any of items 10(a)-(d).
The Spanish version of the PHQ [24] has a sensitivity of 76%
and a specificity of 99% for probable alcohol abuse or
dependence. Participants who have positive scores on these
subscales are briefly interviewed by a clinical psychologist to
confirm the diagnosis. If they present with an eating disorder,
alcohol abuse or dependence, or probable personality disorder
they are excluded from participation in the trial and referred to
their GP for referral to specialized care.
Secondary Outcomes
Disability
The Sheehan Disability Scale [26] is a 5-item self-report scale
that measures subjective impairment during the past month in
three key areas: work, family, and social functioning. Two
additional questions on the SDS are designed to assess the level
of stress and perceived social support in the past week. We used
the Spanish version developed by Bobes et al [38], which has
shown good reliability and validity. The first four items are
rated on an 11-point Likert scale from 0 (no dysfunction) to 10
(maximum dysfunction). The fifth item uses the same scale but
is expressed in percentages from 0% (no social support) to
100% (ideal social support). Scores of 1-3, 4-6, and 7-9 indicate
mild, moderate, or high disability, respectively. Overall scores
of 25 or more indicate a high level of disability. In these cases,
a psychologist will ask participants the following three questions
before excluding them from the study: (1) Are you on sick
leave? (2) Can you do the housework? and (3) Can you engage
socially?
Quality of Life
The World Health Organization Quality of Life Instrument-Short
Form [39] is a 26-item questionnaire used to measure perceived
quality of life in four domains: physical, psychological, social,
and environmental. This instrument is used worldwide, including
in Spain [40], and shows good psychometric properties,
reliability, and validity [41].
Cognitive-Emotional Factors
Several subscales or short questionnaires are used to evaluate
brooding, worries, and cognitive biases. The 5-item Brooding
Scale of the Ruminative Response Scale [42] has been validated
in Spanish with good reliability and validity [43]. The Spanish
version of the Penn State Worry Questionnaire [44,45] is used,
specifically an 8-item version similar to the abbreviated version
(PSWQ-A)[46]. A brief 5-item version of the Inventory of
Cognitive Activity in Anxiety Disorders (IACTA) will be used
to assess attentional biases.
We will use the 10-item validated Spanish version of the
Emotion Regulation Questionnaire, which has been shown to
have good reliability and validity [47,48] to assess emotion
regulation. We will use the 6-item metacognitive beliefs subscale
of the Metacognitions Questionnaire [49] to assess
metacognitions. This has been validated in Spanish with good
reliability and validity [50].
Note that the Spanish version of the PSWQ-A has not been
validated yet and the IACTA is under review. However, the
reliability and validity of these scales and subscales were
recently completed in a subsample of the large PsicAP sample
and results are expected to be published soon.
Treatment Satisfaction
All participants are surveyed to assess their level of satisfaction
with the treatment received; participants rate their satisfaction
on a scale from 0 (high dissatisfaction) to 10 (high satisfaction).
Sample Size
The minimum sample size required to obtain a significant result
has been calculated with the SPSS version 21.0 Sample Power
program (IBM Corp). The study will include at least 563 patients
in each group for a total of 1126 patients, assuming a 20%
attrition or dropout rate. With this sample size, the result will
be statistically significant (85% statistical power) when
comparing both groups, even if they differ by one point only
on the subscales of the PHQ measures, with a standard deviation
of 5. This will enable us to conclude that the result is different
for each group with a 95% confidence level. As previous studies
have reported [11], we expect that the rate of loss to follow-up
will be considerable, despite the strong study design, which
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includes telephone follow-up to reduce attrition. Consequently,
this is likely to be an important limitation of our study.
Patient Recruitment
Patient recruitment is carried out in two phases, as follows.
First Phase
Patients who present with signs or symptoms of anxiety or
depression, negative emotions, or physical symptoms for which
there was no clear biological basis are preselected by the GP
for possible participation. Patients currently being treated with
antidepressants, anxiolytics, and/or hypnotics may also be
invited to participate in the study. The GP will explain the
clinical trial to these patients and ask if they wish to participate.
Prior to study participation, patients will receive written and
oral information in the patient information sheet about the
content and extent of the planned study. This includes
information about the potential benefits and risks for their health.
All patients who agree to participate are required to sign the
informed consent form.
Second Phase
All patients who consent to participate in the trial (ie, have
signed informed consent forms) are contacted by a clinical
psychologist, who will then schedule an appointment to
complete the aforementioned screening questionnaires. Only
patients who meet the study inclusion criteria on the PHQ
subscales—PHQ-15, PHQ-9, PHQ-PD, and GAD-7—are
enrolled, using the cutoff scores and algorithms described above.
All other patients are referred back to their GP for alternative
treatments.
Randomization
Participants are randomly assigned after informed consent or
assent is obtained by a blinded researcher using a
computer-generated allocation sequence, assuring that the groups
are comparable (ie, without differences in key baseline
measures). Each group will include 8-10 patients randomly
allocated either to the experimental group (TD-CBT) or to the
control group (TAU). They receive this allocation information
via email from a graduate student trainee affiliated with the
project. The email also provides login and website information
for the allocated intervention. One clinical psychologist is
assigned to the TD-CBT group; the clinical psychologist
involved in the pre- and posttreatment assessment phases will
not participate in the TD-CBT therapy. Data managers and
statisticians are blinded to the treatment allocation.
Data Collection
After providing written informed consent, the participants are
registered in the treating center. Pre- and posttreatment
assessments are carried out using computerized self-reported
screening tests. All pretreatment assessments are performed at
the treating PC center after scheduling an appointment with the
clinical psychologist. A computer with Internet access is used
to collect data. All data are stored on a general virtual website
(surveymonkey.com). At all posttreatment follow-up
assessments, the same instruments will be completed in person
at the treating center. However, if necessary, we will send the
participant a link by email to enable the patient to complete the
computerized measures at home. Patients are contacted by phone
to encourage completion of the questionnaires. Moreover, those
patients that discontinue or drop out of treatment will still be
invited to complete the posttreatment follow-up assessments,
particularly the first posttreatment assessment.
Data Analysis
Analysis will be carried out using SPSS version 21.0 (IBM
Corp). Intention-to-treat (ITT) analysis will be performed. The
ITT analysis will include all randomized patients in the groups
to which they were randomly assigned. Analysis will take into
account noncompliance, protocol deviations, dropouts, and
anything else that happens after randomization. Using the ITT
approach will enable us to include situations likely to occur in
actual clinical practice. This “real-life” analytical approach
allows us to assess the prognostic balance resulting from the
original random treatment allocation, thus providing a more
accurate estimation of treatment effect. Missing-data analysis
will be computed using Student's t test and chi-square tests.
Variables included in the analysis will be severity level, gender,
and age; this will allow us to ascertain whether unexpected
missing data due to participant dropout are related to chance or
not
The two randomized groups will be compared in the treatment
period; posttreatment; and at 3, 6, and 12 months after treatment
finalization. In addition, within-subject comparisons will be
analyzed, contrasting pretreatment and posttreatment scores.
The within-group and between-group differences will be
examined using mixed-effect models, since these are considered
more accurate than univariate and multivariate repeated
measures of variance [51]. Group differences will be analyzed
after controlling for baseline levels, gender, age, and treatment
center. Additionally, we will estimate the percentage of patients
in each group who experience a 50% decrease in the number
of clinical symptoms and scores by one standard deviation, as
well as the percentage of cases with a probable ED before and
after receiving treatment (according to cutoff criteria).
The TD-CBT therapy will be considered effective if average
scores on ED symptoms—anxiety, depression, and somatic
symptoms—of patients who receive treatment are significantly
lower than average scores of the control group and if effect sizes
(Cohen  d) are low to medium. Both groups will be compared
to test for differences in level of disability—work, family, and
social functioning—quality of life, and treatment satisfaction.
Ethics and Dissemination
Research Ethics Approval
This is a multicenter RCT with medication (N EUDRACT:
2013-001955-11; protocol code: ISRCTN58437086) promoted
by the Psicofundación (The Spanish Foundation for the
Promotion of the Scientific and Professional Development of
Psychology). The trial was approved by the CEIC-APCV—the
national research ethics committee coordinator—and the Spanish
Medicines and Health Products Agency. Approval was received
by both agencies in November 2013, prior to study initiation in
December 2013.
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The CEIC-APCV approved the trial in three centers in the
autonomous communities of Valencia (one center), the Balearic
Islands (one center), and Castilla-La Mancha (one center). The
study was also approved by the local ethics committees of the
first three centers: the CEIC-APCV, the Clinical Research Ethics
Committee of the Hospital Universitario de Albacete
(CEIC-HUA), and the Clinical Ethics Committee of the Balearic
Islands (CEIC-IB).
Protocol Amendments
Six protocol amendments have been presented during the course
of this trial.
Amendment 1
One PC center was added to the autonomous communities of
the Basque Country and was approved by the Clinical Research
Ethics Committee of Euskadi (CEIC-E). In addition, a
substudy—substudy 1—was approved in order to conduct the
study of the psychometric properties of the PHQ subscales of
the PHQ-9, PHQ-PD, and GAD-7 with 15% of the larger
sample. This substudy has been conducted in four PC centers
located in the autonomous communities of Valencia (one center),
the Balearic Islands (one center), the Basque Country (one
center), and Castilla-La Mancha (one center). The substudy was
also approved by the first four local ethics committees: the
CEIC-APCV, the CEIC-HUA, the CEIC-E, and the CEIC-IB.
Amendment 2
Nine centers located in the Community of Madrid were added
to the study. The Clinical Research Ethics Committee of Madrid
approved this amendment, as did the national ethics committee,
the CEIC-APCV.
Amendment 3
One PC center was added to the group of centers in the
autonomous community of Valencia. This center thus became
a full participant in the trial and substudy 1, bringing the number
of PC centers in substudy 1 to five. In addition, several changes
to the first version of the protocol were made, including the use
of the SCID-I to confirm severe MDD and questions to confirm
high disability on the SDS, as described above. Also, new
researchers were added to the study. The amendment was
approved by the national ethics committee—the
CEIC-APCV—and by the relevant local ethics committees.
Amendment 4
Three PC centers, two in Andalusia and one in Cantabria, were
added to the list of participating centers. In addition, substudy
2 was presented, which is a study of the cost-efficiency measures
that are conducted in the PC centers in Madrid and Valencia.
Several changes to the next version of the protocol were made,
including the telephone follow-up posttreatment (see Therapist
Training section above). Finally, new researchers were added
to the study. The amendment was approved by local ethics
committees—the Clinical Research Ethics Committee of
Córdoba and the Clinical Ethics Committee of Cantabria—and
the national ethics committee, the CEIC-APCV.
Amendment 5
Five PC centers were added to the autonomous communities of
Madrid (two centers) and Valencia (three centers) to conduct
the trial. Also, new researchers were added to the study. The
amendment was approved by the local ethics committee—the
Clinical Research Ethics Committee of Madrid—and the local
and national ethics committee, the CEIC-APCV.
Amendment 6
Six PC centers were added to the autonomous communities of
Catalonia (two centers), Galicia (two centers), and Navarra (two
centers) to conduct the trial. Also, new researchers were added
to the study. The national legislative norms have been modified
in Spain and now only one national ethics committee is required
for RCTs. As a result, this amendment was approved by the
national ethics committee, the CEIC-APCV. One new substudy
was also presented. Substudy 3 is a modification of the protocol
design (ie, stepped-wedge trial design), which will be conducted
in two PC centers in Barcelona (Catalonia). In addition, a change
to the next version of the protocol was made with regard to
using the 4-item Patient Health Questionnaire (PHQ-4) to detect
EDs in PC centers by the GP; the aim is to reduce misdiagnoses
of EDs and to accelerate referral to the clinical psychologist in
the second phase of the recruitment process. This will allow us
to determine if the ultrashort measure of the PHQ-4 is an
appropriate tool to help GPs to detect EDs and to reduce the
large number of false negatives. If results are as expected, this
may lead to a proposal for a new referral model in Spanish PC
centers.
Consent
Regarding patient informed consent, prior to study participation,
all patients receive written and oral information in the patient
information sheet about the content and extent of the planned
study. This includes information about the potential benefits
and risks to their health. Patients who agree to participate are
required to sign the informed consent form. In the case of
patients who withdraw from the study, all data will be destroyed
or the patient will be asked if he/she agrees to allow the use of
existing data for analysis in the study.
Patient participation in the study is completely voluntary and
participants can withdraw at any time with no need to provide
reasons and without negative consequences for their future
medical care. The protocols used in this study pose no risk
whatsoever to the participants. TD-CBT is noninvasive at the
cognitive level, except with regard to learning or teaching.
Confidentiality
The study is conducted in accordance with Spanish data security
law. All professionals participating in the study agreed to adhere
to the Helsinki Declaration and to Spanish law. All health care
professionals participating in the study are required to sign a
form indicating their agreement to adhere to the
above-mentioned declaration and Spanish law.
The patient names and all other confidential information fall
under medical confidentiality rules and are treated according to
Spanish data security law. The patient questionnaires are
collected by the researchers (not nurses) and mailed by secure
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transport to the study center in Madrid. All study-related data
and documents are stored on a protected central server and saved
in an encrypted database.
The project complies with current guidelines in Spain and the
European Union for patient protection in clinical trials with
regard to the collection, storage, and keeping of personal data.
Only direct members of the internal study team can access the
data.
Access to Data
The study data are only available upon request. The name(s) of
the contact person(s) to request data are available upon request
to all interested researchers. Legal and ethical restrictions make
data available upon request and are in accordance with the nature
of the data collection.
The CEIC-APCV have some availability restrictions as part of
the legal and ethical control of data from an RCT with
medication.
Data are available from the promoter (Spain) for researchers
who meet the criteria for access to confidential data. Interested
researchers should contact Psicofundación (The Spanish
Foundation for the Promotion of the Scientific and Professional
Development of Psychology) at the registered office at Calle
Conde de Peñalver, 45, 5o izquierda, 28006 Madrid.
Concomitant Care
No concomitant care has been registered.
Dissemination Plans
One of the major objectives of this trial is to convince public
health care administrators to implement, once the efficacy has
been proven, these evidence-based psychological treatments
for EDs in the PC, under the guidance of clinical psychologists.
Given the current situation of the National Health System in
Spain, the number of clinical psychologists will need to be
increased and positions will need to be created at Spanish PC
centers for clinical psychologists.
Results
This study was initiated in December 2013 and will remain open
to new participants until recruitment and follow-up has been
completed. We expect all posttreatment evaluations to be
completed by December 2017, and follow-up will end in
December 2018.
Discussion
Principal Findings
Emotional disorders are common in the community, highly
comorbid, and they often affect personal functioning and
well-being. According to the WHO [9], mental disorders will
generate a large social and economic burden in all countries in
the year 2020. This organization estimates that the current
number of specialized human resources to treat these disorders
is insufficient [9]. Supported by international guidelines such
as the UK National Institute for Health and Clinical Excellence
[10], the WHO recommends implementation of evidence-based
interventions to treat EDs. Psychological treatments such as
CBT are considered the treatment of choice for EDs given their
relative cost-effectiveness in the long term versus
pharmacological treatment [52-54]. Moreover, published reports
indicate that CBT may be even more effective for EDs when a
transdiagnostic approach is used (TD-CBT) [11,55].
In addition to the WHO report described above, other studies
have also found that human resources available for treatment
of EDs, especially clinical psychologists in European countries,
are inadequate [56]. Several reports have demonstrated that
insufficient human resources in Spain can lead to misdiagnosis
and malpractice [18,19]; moreover, this deficit of trained staff
places increased demands on an already oversaturated health
care system. Despite this lack of resources, several Spanish
studies have found that CBT group therapy is highly efficacious
in treating depression in both the short and long term [57], as
well as for other EDs [58].
Given the limited availability of clinical psychologists in
specialized settings, their scant presence in PC centers—the
gateway of patients to the health care system—is not surprising.
According to Serrano-Blanco et al [3], approximately 1 out of
3 patients in the PC setting has some type of ED. This high
prevalence, together with the shortage of clinical psychologists,
underscores the need to increase the availability of these
specialists in PC. This is especially true given the substantial
evidence supporting the effectiveness of CBT.
At present, our group is carrying out this novel project in Spain
to validate the cost-efficiency implementation of psychological
treatment in PC centers. Currently, patients in PC centers are
primarily treated by GPs and psychiatrists. However, we
advocate the use of a collaborative, stepped-care, PC-based
psychological intervention to reduce anxiety, depression,
somatizations, and disability while simultaneously increasing
quality of life. The proposed psychological
intervention—TD-CBT—is a promising intervention delivered
by clinical psychologists following a rigorous scientific protocol
designed to provide optimal care of patients with EDs.
If the results of this clinical trial are positive, as we expect, these
outcomes will provide further support in favor of incorporating
clinical psychologists into the PC setting to administer TD-CBT
group therapy for EDs as the treatment of choice.
Implementation of this model will likely improve treatment
adherence and, consequently, lower the health care burden of
treating EDs. In addition, again assuming that the results are as
expected, this will provide further support to the growing body
of evidence pointing to the value of TD-CBT group therapy in
PC settings. We fully expect that this intervention will improve
the health of patients in the experimental group and will increase
the quality of life and well-being of both patients and relatives.
The ability to offer TD-CBT group therapy would also help to
form therapy groups consisting of patients with several comorbid
disorders, thus further helping in quick group formation. It will
be interesting to study what the implications could be of the
cost-efficiency of this treatment modality.
One of the major interests of this project is the need to increase
the number of clinical psychologists in the Spanish public health
care system. The Spanish government recently acknowledged
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that the public health system needs an additional 7200 clinical
psychologists to reach the European average of 18 per 100,000
people. If the results of this study are similar to those achieved
in studies conducted in other countries (eg, Australia [59,60],
Great Britain [22], Norway [61], and the United States [62]),
then this would provide further empirical evidence in support
of more interventions of this type and thus more clinical
psychologists. Furthermore, the experience gained in this study
will enable us to easily train other clinical psychologists by
applying the manualized TD-CBT program used in this trial,
with no need to further train other professionals.
Study Limitations
This study has several limitations related to the functioning of
Spanish PC centers. GPs are the first point of contact for patients
with EDs and these physicians have only approximately 5-7
minutes to evaluate, diagnose, and offer these patients TAU or
to recommend participation in this clinical trial. Logically, the
recruitment process for this trial could be negatively affected
by these time constraints, especially considering that the GP
must make a concerted effort to motivate and recruit a large
number of patients in a relatively short period of time. Another
limitation is that the PC centers have not been randomly
selected. Despite this limitation, it is important to highlight two
of the main strengths of this study: the large sample of patients
(>1000 patients) and the large number of PC centers (>20)
distributed in a wide geographic range all over Spain.
Another study limitation is that the TD-CBT intervention is
scheduled to last from 12 to 14 weeks and can be affected by
several factors (eg, vacations and availability of participants)
beyond our control. Thus, the follow-up assessments—3, 6, and
12 months posttreatment—might be performed at different time
points. However, we are making every effort to ensure that the
duration and timing of TD-CBT treatment and follow-up
assessments are homogenous among the groups and coincide
with the assessments of the TAU intervention, but we cannot
rule out the possibility of variability.
Additionally, as a limitation similar to other studies of this
nature, we expect a considerable rate of loss to follow-up.
However, the study design includes measures—primarily
telephone and email follow-up—aimed at reducing the rate of
loss. Nevertheless, it seems likely that many patients in both
groups will not complete all follow-up assessments. It is likely
that some patients will discontinue or drop out of treatment.
However, we are registering the number of sessions that patients
in the TD-CBT group attend in order to determine the mean
number of sessions attended; this may improve our outcome
measures, particularly if it shows that some sessions are more
effective than others. Nevertheless, in the TAU group, we are
not registering the number of sessions, as this is an inherent
condition of TAU. As said above, regarding those patients that
drop out of either group, we still invite them to complete the
posttreatment follow-up assessments.
An important aim of this project is to improve the current
referral model, in which GPs refer patients with suspected EDs
to specialist services. This new model seeks to increase
interaction between GPs, clinical psychologists, and specialized
centers through a new referral system based on the
implementation of a stepped-care model. The use of validated
instruments to achieve more accurate diagnoses, together with
the use of more effective treatments, will potentially decrease
the number of GP visits, thereby helping to optimize current
PC resources. In this regard, the role of the clinical psychologists
participating in this clinical trial is crucial.
Once recruitment is completed, patients will continue to receive
care from their primary care GP, who is easily accessible,
without cost to the patient. We are confident of the success of
this treatment program and, if successful, it will add another
tool—TD-CBT—to the available resources for treating EDs.
Clinical guidelines may need to be updated to reflect the study's
outcomes. We expect this study to yield valuable data about the
short- and long-term efficacy of TD-CBT group therapy for
EDs applied by clinical psychologists in a PC setting. Our
findings could help design stronger and more effective public
health strategies and treatments, leading to better care of patients
with these disorders.
Finally, it is important to note that this project and its design
are novel in the PC setting in Spain. If the results are as
expected, this project could serve as a model for use in other
areas or services of the National Health System in Spain and
even in other countries.
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